Allison Bragg, PharmD, BCPPS

Allison Bragg, PharmD, BCPPS

  • Residency Programs Coordinator
  • Assistant Professor, The University of Tennessee Health Sciences Center, Department of Clinical Pharmacy and Translational Science

Board Certification

  • BCPPS

Education

  • BS – University of Mississippi School of Pharmacy, University, Mississippi
  • PharmD – University of Mississippi School of Pharmacy, University, Mississippi

Post-Graduate Training

  • PGY1 Pharmacy Practice Residency – St. Louis Children’s Hospital, St. Louis, Missouri
  • PGY2 Oncology Pharmacy Residency – St. Jude Children’s Research Hospital, Memphis, Tennessee

Focused Area of Practice

  • Pharmacogenomics

Honors/Awards

  • 2020  Clinical Care Improvement Award for Clinical Pharmacy Services, St. Jude Children’s Research Hospital 
  • 2018  Improvement Award for Chemotherapy Service, St. Jude Children's Research Hospital Clinical Care

St. Jude Committee Service

  • Teen and Emerging Adults (TEA) Committee
  • Graduate Medical Education Committee
  • Pharmacogenomics Oversight Committee
  • Residency Advisory Committee
  • Residency Directors' Committee

Pharmacy Organizations/Committee Service

  • Clinical Pharmacogenetics Implementation Consortium
  • Pharmacogenomics Global Research Network
  • American Society of Health System Pharmacists
  • Pediatric Pharmacy Association
  • Hematology/Oncology Pharmacy Association
  • American College of Clinical Pharmacy
  • Tennessee Pharmacists Association
  • Tennessee Society of Health-System Pharmacists Residency Committee

Selected Publications

Moody J, Barker PJ, Sciasci J, Pauley JL, Bragg A, McMillan C, Triplett BM, Swanson HD. Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission. Pediatr Blood Cancer. 2024; 71 (10):e31223

Drennan CN, Pauley JL, Christensen AM, Jacobs TW, Bragg AW, Porter JS, Bourque MS. Pharmacist Effect on Discharge Follow-Up Education in Pediatric Oncology Outpatient Clinics: A Quality Improvement Study. J Pediatr Pharmacol Ther. 2023;28(3):262-267.ddd

Talleur A, Qudiemat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman AY, Srinivasan A, Velasquez MP, Obeng EA, Willis CM, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou S, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood BA, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S. Preferential expansion of CD8+ CD18-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.Blood Adv 2022 Apr 21:bloodadvances.2021006293. doi: 10.1182/bloodadvances.2021006293. Epub ahead of print. PMID: 35446934.

Sauer H, Crews KR, Pauley JL, Bourque MS, Bragg AW, Triplett B, Morrison RR, Hall, EA. Evaluation of Aminophylline for the Treatment of Acute Kidney Injury in Pediatric Hematology/Oncology Patients.  J Pediatr Pharmacol Ther. 2021 Jun; 26(5): 484-90.

Lambrix AA, Swanson HD, Pauley JL, Bragg AW, Carias DC, Bourque MS, Zhou Y, Cheng C, Greene WL, Maron G. Experience using intravenous posaconazole in pediatric and young adult oncology patients. J Antimicrob Chemother. 2020; 75 (12): 3682-3687.

Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson HD, Wolf J, Greene W. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrob Agents Chemother. 2018 Jul 27;62(8).

Last update: October 2024

Close
Close